文献速递肝病

肝纤维化评分可预测美国人群的肝病死亡率

Liver fibrosis scores predict liver disease mortality in the United States population.
PubMed 文献 · Hepatology · 2017-05-16

研究基于第三次美国国家健康与营养调查(1988-1994)中14,841名病毒性肝炎阴性成人,随访至2011年(最长23年),用APRI、FIB-4、NFS和Forns评分预测肝纤维化。结果显示纤维化评分升高与肝病死亡率和全因死亡率升高相关。作者认为用常见临床纤维化指标进行风险分层以管理肝脏健康值得进一步研究。

要点

  • APRI中高组肝病死亡HR 9.44(95%CI 5.02-17.73)。
  • FIB-4中、高组肝病死亡HR分别为3.15和25.14。
  • Forns中、高组肝病死亡HR分别为3.58和63.13,NFS高组HR 6.52。

核心结论

  • 在美国人群中,较高的肝纤维化评分与肝病死亡率和全因死亡率升高相关。
  • 作者认为用常见临床纤维化指标进行风险分层以管理肝脏健康值得进一步研究。

研究设计与样本

  • 基于第三次美国国家健康与营养调查(1988-1994)的前瞻性人群调查,纳入14,841名病毒性肝炎阴性成人。
  • 通过链接国家死亡索引记录被动随访至2011年,最长随访23年,死亡原因取自死亡证明的根本或 contributing 死因。
  • 用APRI、FIB-4、NFS和Forns评分预测肝纤维化,用Cox比例风险回归计算死亡HR并校正死亡危险因素。

主要发现

  • 随访期间全因累积死亡率为28.0%,肝病(含原发性肝癌)累积死亡率为0.82%。
  • APRI中高组肝病死亡HR 9.44(95%CI 5.02-17.73)。
  • FIB-4中组肝病死亡HR 3.15(95%CI 1.33-7.44),高组HR 25.14(95%CI 8.38-75.40)。
  • NFS高组肝病死亡HR 6.52(95%CI 2.30-18.50)。
  • Forns中组肝病死亡HR 3.58(95%CI 1.78-7.18),高组HR 63.13(95%CI 22.16-179.78)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为用常见临床纤维化指标进行风险分层以管理肝脏健康值得进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Fatty liver disease is common in the United States and worldwide due to changing lifestyles and can progress to fibrosis and cirrhosis contributing to premature death. We examined whether liver fibrosis scores were associated with increased overall and disease-specific mortality in a United States population-based prospective survey with up to 23 years of linked-mortality data. Data were analyzed from 14,841 viral hepatitis-negative adult participants in the third National Health and Nutrition Examination Survey, 1988-1994. Liver fibrosis was predicted using the aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) score, nonalcoholic fatty liver disease fibrosis score (NFS), and Forns score. Participants were passively followed for mortality, identified by death certificate underlying or contributing causes, by linkage to National Death Index records through 2011. Hazard ratios (HR) for mortality were calculated using Cox proportional hazards regression to adjust for mortality risk factors. During follow-up, cumulative mortality was 28.0% from all causes and 0.82% with liver disease, including primary liver cancer. Elevated liver disease mortality was found with an intermediate to high APRI (HR, 9.44; 95% confidence interval [CI], 5.02-17.73), intermediate (HR, 3.15; 95% CI, 1.33-7.44) or high (HR, 25.14; 95% CI, 8.38-75.40) FIB-4 score, high NFS (HR, 6.52; 95% CI, 2.30-18.50), and intermediate (HR, 3.58; 95% CI, 1.78-7.18) or high (HR, 63.13; 95% CI, 22.16-179.78) Forns score. Overall mortality was also greater with higher fibrosis scores. CONCLUSION: In the United States population, higher liver fibrosis scores were associated with increased liver disease and overall mortality. Liver health management with common clinical measures of fibrosis risk stratification merits further investigation. (Hepatology 2017;66:84-95).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017. PMID: 28195363. doi:10.1002/hep.29113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。